The study involves several medications that are used as part of the adjuvant treatment. These include ONCOVIN (vincristine sulfate), THIOTEPA (found in both THIOTEPA GENOPHARM and TEPADINA), ENDOXAN (cyclophosphamide), ETOPOSIDE TEVA (etoposide), and CARBOPLATINE TEVA (carboplatin). These medications are administered through injections or infusions, which are methods of delivering the drugs directly into the bloodstream or body. Some patients may receive a placebo, which is a substance with no active medication, to help compare the effects of the actual drugs.

Participants in the study will receive these treatments and be monitored over time to see if the cancer returns and to evaluate any side effects from the treatments. The study will also look at the long-term effects of the treatments and how they impact the patients’ overall health. Additionally, researchers will study the genetic makeup of the tumors and use imaging techniques like MRI to detect any spread of the cancer beyond the eye. The study aims to provide valuable information that could improve treatment strategies for children with retinoblastoma in the future.

The study is divided into three parts. In the first part, patients with certain types of retinoblastoma receive intravenous chemotherapy with etoposide and carboplatin, followed by a treatment that combines chemotherapy and heat therapy, known as chemothermotherapy. The second part involves patients with more advanced retinoblastoma receiving melphalan through a method called intra-arterial chemotherapy, where the drug is delivered directly to the eye’s blood supply. The third part of the study includes patients with more severe cases, who receive a combination of three drugs, including vincristine sulfate, along with local treatments like laser therapy and cryotherapy, which uses extreme cold to destroy cancer cells.

The study aims to determine how well these treatments work in saving the eye and preventing the need for radiation therapy. It also looks at the side effects of the treatments and the risk of the cancer coming back. The study will follow patients over time to monitor their response to the treatments and any potential long-term effects. The ultimate goal is to find effective ways to treat retinoblastoma while preserving the patient’s vision and quality of life.

The purpose of the study is to assess how well these treatments work in controlling the disease and preserving vision. The study is divided into two parts. The first part focuses on the use of intra-arterial chemotherapy (IAC), which involves delivering chemotherapy directly to the eye, to see how well it controls the disease. The second part evaluates the visual function of patients who receive other conservative treatments, such as intravenous (IV) chemotherapy combined with local eye treatments or local treatments alone, which are less invasive.

Participants in the study will receive one of the treatment options and will be monitored over time to see how well the treatments work in preserving the eye and vision. The study will also look at the visual outcomes based on criteria set by the World Health Organization (WHO). The goal is to find the most effective treatment strategy for children with retinoblastoma, ensuring the best possible visual outcomes while controlling the disease.